First commercial batch of Covaxin released from Bharat Biotech's new plant

The first commercial batch of Covaxin was released on Sunday from the new plant of Bharat Biotech at Ankleshwar in Gujarat's Bharuch district by Union Health Minister Mansukh Mandaviya

Bharat Biotech, Covaxin
Photo: Shutterstock
Press Trust of India Ankleshwar
1 min read Last Updated : Aug 30 2021 | 1:10 AM IST

The first commercial batch of Covaxin was released on Sunday from the new plant of Bharat Biotech at Ankleshwar in Gujarat's Bharuch district by Union Health Minister Mansukh Mandaviya.

"Vaccination is the most important thing to strengthen the country's fight against coronavirus. Released the first commercial batch of #COVAXIN from Bharat Biotech's plant at Ankleshwar, Gujarat today. This will increase the supply of vaccine in the country and will help the vaccine reach every Indian," Mandaviya tweeted soon after the event.

The government had earlier this month given approval to Bharat Biotech's Ankleshwar-based manufacturing plant to produce anti-COVID-19 vaccine Covaxin.

In May, Bharat Biotech announced that it planned to produce an additional 200 million doses of Covaxin at its subsidiary's Ankleshwar-based facility. The Hyderabad-based firm had noted that it would utilise the manufacturing plant of its wholly-owned unit, Chiron Behring, to add another 200 million doses of Covaxin.

India administered 63.09 crore doses of COVID-19 vaccination in a nationwide drive till Sunday morning, as per the data released by the Union Health Ministry.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bharat BiotechCoronavirus VaccineMansukh Lal Mandaviya

First Published: Aug 29 2021 | 12:20 PM IST

Next Story